International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 014-020
RETROSPECTIVE ANALYSIS OF TREATMENT PROTOCOLS AND PROGNOSTIC FACTORS HAVING IMPACT ON TREATMENT IN EARLY STAGE HODGKIN'S DISEASE PATENTS
GÜLÇİN ERTAŞ1, FAİK ÇETINDAG1, O. NURİ SÜNTER1, A. RIZA ÜÇER1, AYŞEN DİZMAN1, AYŞE HİÇSÖNMEZ1, M. ERDOĞAN GİDER1
Sağlık Bakanlığı Onkoloji Hastanesi Radyasyon Onkolojisi Bölümü, ANKARA
Keywords: hodgkin's disease, treatment, prognostic factors
In this study, therapeutic protocols and prognostic factors having impact on treatment in early stage Hodgkin's disease patients who were treated in Ankara Oncology Hospital were evaluated retrospectively. Prognostic factors and treatment outcomes of 55 patients with stage I-II Hodgkin's disease who were treated between 1993-1998 were evaluated retrospectively. Out of 36 patients with stage IA-IIA, 22 patients were treated with radiotherapy alone whereas 12 patients were treated with combined radiochemotherapy, and 2 patients were treated with chemotherapy alone. Out of 19 patients with Stage IB-IIB, 8 patients were treated with radiotherapy alone, 8 patients were treated with chemotherapy and radiotherapy combinations and 3 patients were treated with chemotherapy alone. Median follow-up 37.6 months. B symptoms and ESR > 50mm/h (Erythrocyte sedimentation rate) were the significant prognostic factors on the relapse free survival. The presence of bulky peripheral lymphadenopathy (10 cm) was associated with poor overall survival (p:0.002). Five-year overall survival was 86%. It was 84% in the radiotherapy arm, 81% in the radiotherapy and chemotherapy arm (p=0.66). Five-year relapse free survival was 69%. It was 64% in the radiotherapy arm, 77% in the radiotherapy and chemotherapy arm (p=0.97). We observed relapse in 11 patients out of 55. Nine of them (81%) were in the non-irradiated regions and accounted for the majority of the relapses. ESR and B symptoms for disease free survival and the presence of bulky peripheral lymphadenopathy for overall survival are the most significant prognostic factors found in this retrospective study.
GÜLÇİN ERTAŞ1, FAİK ÇETINDAG1, O. NURİ SÜNTER1, A. RIZA ÜÇER1, AYŞEN DİZMAN1, AYŞE HİÇSÖNMEZ1, M. ERDOĞAN GİDER1
Sağlık Bakanlığı Onkoloji Hastanesi Radyasyon Onkolojisi Bölümü, ANKARA
Keywords: hodgkin's disease, treatment, prognostic factors
In this study, therapeutic protocols and prognostic factors having impact on treatment in early stage Hodgkin's disease patients who were treated in Ankara Oncology Hospital were evaluated retrospectively. Prognostic factors and treatment outcomes of 55 patients with stage I-II Hodgkin's disease who were treated between 1993-1998 were evaluated retrospectively. Out of 36 patients with stage IA-IIA, 22 patients were treated with radiotherapy alone whereas 12 patients were treated with combined radiochemotherapy, and 2 patients were treated with chemotherapy alone. Out of 19 patients with Stage IB-IIB, 8 patients were treated with radiotherapy alone, 8 patients were treated with chemotherapy and radiotherapy combinations and 3 patients were treated with chemotherapy alone. Median follow-up 37.6 months. B symptoms and ESR > 50mm/h (Erythrocyte sedimentation rate) were the significant prognostic factors on the relapse free survival. The presence of bulky peripheral lymphadenopathy (10 cm) was associated with poor overall survival (p:0.002). Five-year overall survival was 86%. It was 84% in the radiotherapy arm, 81% in the radiotherapy and chemotherapy arm (p=0.66). Five-year relapse free survival was 69%. It was 64% in the radiotherapy arm, 77% in the radiotherapy and chemotherapy arm (p=0.97). We observed relapse in 11 patients out of 55. Nine of them (81%) were in the non-irradiated regions and accounted for the majority of the relapses. ESR and B symptoms for disease free survival and the presence of bulky peripheral lymphadenopathy for overall survival are the most significant prognostic factors found in this retrospective study.